New drug hope for rare salivary gland cancer
NCT ID NCT05074940
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether amivantamab can shrink tumors or slow disease in 21 people with recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer. Participants receive weekly or biweekly infusions of the drug. The main goal is to see how many patients respond, with secondary measures of progression-free survival and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amivantamab
What this could lead to
If it works, this could offer a new treatment option for people with advanced adenoid cystic carcinoma that has stopped responding to other therapies.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Rogel Cancer Center - University of Michigan Health
Ann Arbor, Michigan, 48109, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
Washington University - School of Medicine in St. Louis
St Louis, Missouri, 63130, United States